Lung Neuroendocrine Carcinoma — Trials

Lung Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,113 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 389
Recruiting: 206
Ph III recruiting: 27
Growth YoY: −2.9%
Industry share: 43%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (159)

clinicaltrialsPublishedShowing 301–350 of 1,113 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07434518	A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC	recruiting	—	500	Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER	1	Feb 25, 2026	clinicaltrials
NCT04471727	A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)	active not recruiting	Phase 1 / Phase 2	232	Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)